» Articles » PMID: 21912764

Estimating Benefits of Therapy in Crohn's Disease in Terms of Indirect Costs

Overview
Specialty Gastroenterology
Date 2011 Sep 14
PMID 21912764
Citations 1
Authors
Affiliations
Soon will be listed here.
Citing Articles

Neutralization of Inflammation by Inhibiting and Secretory Phospholipase A by Ethanol Extract of L.

Giresha A, Pramod S, Sathisha A, Dharmappa K Pharmacognosy Res. 2017; 9(2):174-181.

PMID: 28539742 PMC: 5424559. DOI: 10.4103/0974-8490.204650.

References
1.
Bernstein C, Papineau N, Zajaczkowski J, Rawsthorne P, Okrusko G, Blanchard J . Direct hospital costs for patients with inflammatory bowel disease in a Canadian tertiary care university hospital. Am J Gastroenterol. 2000; 95(3):677-83. DOI: 10.1111/j.1572-0241.2000.01845.x. View

2.
Odes S . How expensive is inflammatory bowel disease? A critical analysis. World J Gastroenterol. 2008; 14(43):6641-7. PMC: 2773305. DOI: 10.3748/wjg.14.6641. View

3.
Panaccione R, Loftus Jr E, Binion D, McHugh K, Alam S, Chen N . Efficacy and safety of adalimumab in Canadian patients with moderate to severe Crohn's disease: results of the Adalimumab in Canadian SubjeCts with ModErate to Severe Crohn's DiseaSe (ACCESS) trial. Can J Gastroenterol. 2011; 25(8):419-25. PMC: 3186726. DOI: 10.1155/2011/724813. View